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Today Africa is confronted with a huge burden of Human Immunodeficiency Virus 
(HIV) associated tuberculosis (TB). In 2010, 77% of the TB in Lesotho was HIV 
associated. 
The problem is intensified by many factors, such as the timing of initiation of 
antiretroviral therapy (ART), separation of HIV and TB services that discourages 
people from seeking care and the policies governing the treatment of HIV and TB.  
Aim 
The aim of this study is to compare the effectiveness of late versus early 
commencement of ART in adults living with HIV associated TB in Lesotho in 2012.  
Method 
An observational, analytic cross-sectional study design was conducted. Three out 
of 17 hospitals were randomly selected and data for patients with HIV-associated 
TB who had completed TB therapy during the study period (January to March 
2012) was extracted from the hospitals’ TB registers.   
Results 
Of the 247 adults living with HIV associated TB, 80 (32%) were started on ART 
early (4 weeks or less), 100 (41%) were started late (after 4 weeks) and 67 (27%) 
received no ART at all. The unadjusted results show that early initiators were 6 
times more likely to have a successful TB outcome (OR 6.2: 95%CI: 3.7 to 27.5) 
xiv 
 
relative to the group who had no ART. The difference was statistically significant 
(p<0.001). Interestingly those who commenced ART late also were six times more 
likely to have a successful TB outcome (OR 5.6: 95% CI: 2.8 to 11.2) relative to 
the group who had no ART. 
Discussion 
This study provides evidence that in Lesotho, early initiation of ART in adults living 
with HIV associated TB has not been fully implemented. Only a third were 
commenced on ART early after starting TB treatment. This study demonstrated 
however, that even those who commenced ART late performed much better than 
those who were not prescribed ART. This therefore highlighted that successful TB 
treatment outcomes were not dependent on when ART was initiated.  
Recommendations 
The Lesotho Ministry of Health should ensure early initiation of ART in people 
living with HIV associated TB in order to improve their TB outcomes.  
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1 CHAPTER ONE: INTRODUCTION 
Human Immunodeficiency Virus (HIV) associated tuberculosis (TB) constitutes one of 
the leading causes of death in Africa. Lesotho, as an independent nation, is no 
exception. It has experienced high levels of mortality due to TB, occurring in people 
living with HIV and Acquired Immunodeficiency Syndrome (AIDS) (PLHIV). Research 
has shown that TB is more likely to occur in those infected with HIV than in those who 
remain uninfected. 1 In 2010, 77% of the TB in Lesotho was HIV associated, and 
there has arisen a demand for action aimed at ensuring those co-infected both 
survive and achieve better TB outcomes. 
Lesotho is faced with high levels of mortality and poor TB outcomes, occurring in 
people living with HIV associated TB. Furthermore, initiation of antiretroviral therapy 
(ART) within a month of TB treatment commencement among adults with HIV 
associated TB the policy in Lesotho.a The problem is important because the 
economically active population (15 to 64 year olds) is the most affected sector and 
this exerts adverse impact on the economy of the country. The study will contribute 
evidence that will enable the authorities to be aware of the problem and the need to 
commence ART in people living with HIV associated TB early as it has been found to 
be efficacious in experimental studies.  
                                            
a The policy since April 2011 in Lesotho, is that all people living with HIV associated TB on TB 





Before implementation of early initiation of ART in adults living with HIV associated 
TB, initiation of ART was based on their CD4 count and this approach did not yield 
favourable results. 2 The TB and HIV services were not user-friendly as those co-
infected could not gain access to all services under one roof, and this factor 
discouraged their seeking appropriate treatment and care.2 In 2011, Lesotho revised 
the national guidelines for TB and HIV co-management, incorporating the new 
recommendations of the World Health Organization (WHO). These National 
Antiretroviral Therapy Guidelines (Guidelines) recommended that those individuals 
living with HIV associated TB be initiated on ART immediately (i.e. within two to four 
weeks) after commencing TB treatment. 2 The Guidelines also indicated that all 
facilities should integrate TB and HIV services in order to ensure effective TB and 
HIV co-management, which includes early initiation of ART and other necessary 
services for PLHIV associated TB. 2  
In this opening chapter, I will describe the background to this study on assessing the 
effectiveness of HIV-associated TB in Lesotho. The aim of this study, objectives of 
the study, type of research, the definitions of words and phrases, statement of the 
problem and the present state of knowledge and expertise are all vital factors that will 
be described. 
1.1 Aim 
The aim of this study is to compare the effectiveness of late versus early 
commencement of ART in adults living with HIV associated TB in three hospitals in 





The objectives of this study are: 
• To describe the profile of people living with HIV associated TB; 
• To measure TB outcomes in PLHIV associated TB initiated both early and late 
on ART; 
• To identify predictors associated with the effectiveness of early initiation of 
ART in adults living with HIV associated TB; and 
• To make recommendations to authorities as to how the programme can be 
improved.  
1.3 Type of research 
This is health systems research.  
1.4 Definitions 
• HIV associated TB, occurs when an individual is co-infected with both TB and 
HIV. 
• Early initiation of ART, involves initiation of ART for people living with HIV 
associated TB within two to four weeks after starting TB treatment. 
• Late initiation of ART is when ART is only commenced for people living with HIV 
associated TB any time after four weeks of starting TB treatment.  
• The Type of TB patient is categorised as to whether the patient is diagnosed with 
TB for the first time, after defaulting, after failing the first course of TB treatment, 
after relapsing or for any other cause excluding the mentioned ones. 
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• Treatment category, refers to whether a patient is in category one (I) or two (II) 
depending on whether the person infected with TB receives (I) the standard TB 
treatment regimen for those diagnosed with TB for first time or whether they 
received (II) the alternate TB treatment regimen reserved for those who have 
been treated for TB before. 
• Treatment outcome is the end result of every PLHIV associated TB who 
commences TB treatment.  
1.5 Statement of the problem 
Lesotho had a population of 1 880 661 and 13 520 cases of TB were notified in 
2010.2 Out of these cases, 76% were living with HIV associated TB. Lesotho, like 
other low income countries has been greatly affected by TB and HIV and this has 
further led to high levels of mortality related to these two infections and which 
negatively affects the health service.2 Consequently, the reported annual TB 
notification incidence risk was 640 per 100 000 population in 2009. The high levels of 
HIV associated TB are the primary reason contributing to the reduction in life 
expectancy at birth, declining to 35 years in the country in 2010. 2 Moreover, the 
Lesotho Ministry of Health and Social Welfare (MOHSW) reported that in 2011, HIV 
testing had occurred in 82% of TB patients of which 76% were found to be living with 
HIV.3 Amongst those that were living with HIV (irrespective of whether they were 
infected with TB or not), 90% were started on cotrimoxazole and 40% were initiated 
on ART in 2011.3 
In 2011, the MOHSW adopted a policy of initiating people with HIV associated TB on 
ART within a month of commencing TB therapy, which should increase their survival. 
2 Increased survival has been reported in other countries such as its Rwanda, where 
both improved TB treatment outcomes and the CD4 count in adults living with HIV 
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associated TB that were initiated on ART within a month of commencing TB 
treatment occurred.4 The efficacy of early initiation of ART in people living with HIV 
associated TB is around 90%, a positive development, which strongly implies that 
people living with HIV associated TB are started on ART early. 5   
1.6 What is known so far? 
A renewed epidemic of TB has been present in Lesotho commencing in 1985. 7 There 
is strong evidence that HIV is the underlying factor fueling the epidemic. A condition 
where both diseases have infected an individual (HIV associated TB) is now common 
in sub-Saharan Africa, a serious public health development, which has resulted in 
high levels of mortality in those co-infected. 7 The issue is, where there is HIV 
associated TB, the CD4 count decreases and viral load accordingly increases, 
leading to the worsening of AIDS. 7 
Early initiation of ART serves as one of the strategies that have been proven to be 
effective in improving survival in people living with HIV associated TB. 5 Survival was 
increased by 60% to 90% among people living with HIV associated TB in countries 
where early initiation of ART was introduced.5 The study that was conducted in South 
Africa in 2006 by the International Center for AIDS Care and Treatment Programs 
(ICAP) recommended that people living with HIV associated TB should be started on 
ART within four weeks as mortality is reduced by early initiation of therapy.6 
Additionally, Colebunders & Lambert (2002) allude to the fact that “about a third of 
the 36 million people living with HIV worldwide are co-infected with Mycobacterium 
tuberculosis; 70% of those co-infected live in sub-Saharan Africa.” 5 Sub-Saharan 
African countries have about 70% of those globally with HIV associated TB.5 For this 
reason, knowledge about the condition is important, a vital instrument allowing the 
remedy and solution of problem.   
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1.7 Organisation of the report 
The dissertation is divided into eight chapters: 
In Chapter 1: Introduction, the background to the topic is described briefly, the 
purpose of the research and the specific objectives are outlined. 
The literature review in Chapter 2 provides an analysis of the existing literature on the 
timing of ART in patients with HIV associated TB and the TB treatment outcomes. 
In Chapter 3: Materials and Methods, the study design, study population, data 
sources, sampling methods, variables and statistical analysis applied in this study are 
further explored. The reliability and validity of the study and handling of bias and 
limitations are also described. 
In Chapter 4, the results are presented. 
In Chapter 5: Discussion of the results is undertaken. 
In Chapter 6, conclusion and recommendations based on the results of the study are 
described. 
In Chapter 7: References to all materials used are shown. 
Chapter 8 contains the appendices, which include the data collection tool used, 
permission letters to hospitals, permission to conduct the research obtained from the 
KwaZulu-Natal Biomedical Research Ethics Committee (BREC) and  letter of 
registration of the project with the School of nursing and Public health Research and 
Higher Degrees Committee. 
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1.8 Summary of the chapter 
The introductory chapter gives a background to HIV associated TB and the 
effectiveness of its treatment. HIV associated TB is a major problem facing Africa 
today and Lesotho constitutes no exception. It has been shown that survival and TB 
outcomes were much improved when ART was initiated early in people living with 
HIV associated TB. It is important to measure the effectiveness of this intervention in 
a low income country with a large HIV associated burden such as Lesotho. 
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2 CHAPTER TWO: LITERATURE REVIEW 
In this chapter, and issues related to access of early initiation of antiretroviral therapy, 
clinical improvement with early initiation of ART, changes in CD4 and viral load 
(immunity) and challenges of early initiation of ART are explored. It will reflect 
purpose of the literature review; the scope of what has already been studied and 
research that has been undertaken and reported in the scientific literature.  
2.1 Purpose of the literature review 
The purpose of this literature review was to establish: 
• What is currently documented about effectiveness of early initiation of ART in 
PLHIV and TB globally, in the African continent and in South Africa; 
• Challenges and successes encountered in implementing the guidelines 
relating to early initiation of ART in PLHIV and TB;  
• Outcomes related to early initiation of ART in PLHIV and TB conducted in 
different study settings. 
2.2 Scope of literature review 
The literature was searched using a number of databases – Medline, PubMed, PLOS 
Medicine, Journal of Acquired Immune Deficiency Syndromes, and Google scholar 
and Google search engine. The key terms “early initiation of ART in PLHIV and TB”, 
“early ART initiation”, “TB and HIV co-infection” and “HIV and TB” were used in the 
literature search. However, some material such as the Lesotho TB and guidelines 
was accessed from the Ministry of Health. 
2.3 Problem framework 
Figure 1 below shows the problem framework that was considered for effectiveness 
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of early ART initiation. It has four components namely individual factors, facility 
factors, national factors and the assessment of the study. Lastly, at the center of the 



















• Accessibility of health facility 
TB/HIV services 
• Do all facilities provide 
TB, HIV or TB/HIV 
integrated services? 
• Health education 
Effectiveness of early ART 
initiation 
Facility Factors 
• Do all facilities provide TB, HIV or 
TB/HIV integrated se vices? 
• Are patients initiated early or late on 
ART? 
• Health education 
National Factors 
• How will the study 
benefit Lesotho? 
• What can be learned 
from the study? 
• What policies can be 
made from the study? 
• What can hinder early 
initiation of ART? 
Assessment 
• Who will be interested in 
the study? 
• What was the situation 
before early initiation of 
ART? 
• How will the outcome 




2.4 Access of early initiation of ART in people with HIV associated TB 
It is important to establish whether people living with HIV and TB in different settings 
have access to ART and TB services. Many factors could hinder access and this will 
be elaborated further by studies discussed below. 
An observational, cross-sectional study conducted in India in 2005 on this particular 
question of HIV associated TB showed that timely initiation of ART markedly 
improved the outcomes of people living with this specific combination of diseases .1   
Furthermore, it was reported that although there had been no prior evidence of the 
appropriate time to initiate ART in people living with HIV associated TB, this 
retrospective study demonstrated that early initiation of ART was associated with 
reduced mortality and disease progression.  
In 2002, a study conducted in London among 347 HIV-1 patients presenting with 
culture proven TB confirmed that most people living with HIV associated TB who died 
with low CD4 counts were not prescribed ART. Furthermore, some were only started 
on ART a few months prior to death.8 The study showed the importance of early 
initiation of ART in people living with HIV associated TB, as it improves survival. 
A retrospective study conducted in Iran between 2002 and 2006 revealed that, 
among 69 hospitalized patients living with HIV associated TB, 28% of those who 
started ART eight weeks after commencing TB treatment died, while only 4.5% died, 
in those who were started two weeks after commencing TB therapy.9 Results from 
this study also confirmed that early initiation of ART in people living with HIV 
associated TB is better than late initiation.  
Additionally, early initiation of ART in people living with HIV associated TB may not 
only lead to improved treatment outcomes but it may also assist in faster sputum 
conversion.10 The Indian Council of Medical Research, reported the following insight: 
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“Early initiation reduces mortality and morbidity due to HIV and tuberculosis with 
faster sputum conversion. The Starting Antiretrovirals at Three Points in Tuberculosis 
Therapy trial reported a 56% lower mortality among 214 patients who commenced 
ART during tuberculosis treatment, compared with 215 patients who waited until TB 
therapy had been completed.10 
Furthermore, it has been pointed out that “Collaboration between TB and HIV & AIDS 
programmes in making ART available to HIV-positive TB patients will contribute to 
speeding up progress towards achieving the ‘3 by 5’ target (3 million people on ART 
by 2005).”11 As soon as a TB patient tests positive for HIV, he/she must be started on 
Cotrimoxazole Preventive Therapy (CPT). These patients must now also be started 
on ART within two months of commencing their TB treatment.12   
A retrospective cohort study conducted in Thailand among 1003 patients living with 
HIV associated TB between January 2000 and December 2004, revealed that, 
“Antiretroviral therapy substantially reduces mortality rate among HIV/TB-co infected 
patients. Initiation of ART within 6 months of TB diagnosis is associated with greater 
survival.” 13 This observational study showed high levels of survival, which ranged 
between 88% and 96% in people living with HIV associated TB who began ART and 
low levels of survival of about 9% to 44% of those not on ART.13 
The WHO revised the HIV guidelines in 2010 and indicated that people living with 
HIV associated TB must be started on ART within two to four weeks after 
commencing TB treatment. 2 Thus, clinical improvement with early initiation of ART in 
people living with HIV associated TB should also be an important subject of study as 
it reflects the true picture of treatment outcomes. 2 
A clinical trial conducted in Lesotho in 2013 among 444 HIV associated TB patients 
indicated that there is evidence that people living with HIV associated TB have better 
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survival rates when started on ART early. 14 However, the country is still faced with 
the challenge of people who do not start ART within the recommended time while 
others simply do not remain in care. 14 
As shown by the studies above, early initiation of ART in people living with HIV 
associated TB reduces mortality and improves TB treatment outcomes. The evidence 
suggests that the most appropriate time of ART initiation is soon after commencing 
TB therapy.  
2.5 Clinical Improvement with early initiation of ART in people with HIV 
associated TB 
In this section, studies relating to clinical improvement due to early initiation of ART in 
people living with HIV associated TB will be discussed. The focus will be onCD4 cell 
count, weight gain and sputum conversion. 
A prospective study conducted in 5 hospitals in Cambodia (2006 to 2009) where 661 
patients (332 receiving early ART and 329 receiving late ART) were enrolled and 
demonstrated that there were fewer new AIDS-defining illnesses due to early 
initiation of ART in adults living with HIV associated TB. Only 16% of the patients 
receiving earlier ART compared with 27% of the patients receiving later ART 
developed a new AIDS-defining illness or died (Incidence Rate Risk 95% CI: 1.5 to 
20.5; p = 0.02).”15 
A study conducted in Durban showed that initiating ART early in people living with 
HIV associated TB improves survival, even in patients with low CD4 counts. This 
report, based on the Starting Antiretroviral Therapy at Three Points in Tuberculosis 
(SAPiT) trial, compared early ART initiation (within 4 weeks of commencing TB 
therapy) and late initiation of ART (between 4 and 12 weeks of commencing TB 
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treatment) among 642 South Africans infected with HIV and having smear-positive 
pulmonary TB confirmed the efficacy of early initiation. The incidence of AIDS or 
occurrence of death among patients with a CD4 count less than 50 cell/µ was 8.5 and 
26.3 cases per person-years (incidence-rate ratio 0.32; 95% CI: 0.07 to 1.13; p = 
0.06) in the early and late ART initiation groups respectively.16  
In Hong Kong, another study confirmed that improved survival was associated with 
early initiation of ART in patients with HIV associated TB. In this study involving 260 
patients living with HIV associated TB, 32 were started on ART within two months of 
commencing TB treatment (early group). Results revealed early initiation of ART was 
associated with favourable outcomes (cure or treatment completion without relapse) 
at 24 months (91% v 67%; p=0.007) compared to those who were only started on 
ART at a later stage (beyond two months of starting TB treatment).17 
A study conducted in Boston in 2011 reported that among 806 individuals enrolled 
from 26 sites on 4 continents, 405 received immediate ART (median of 10 days) 
while 406 received early ART (within 10 weeks from start of TB treatment).16 The 
median start ART time for the immediate group was 10 days and that of the early 
ART was 40 days. Results showed that only 13% of those who received immediate 
ART experienced AIDS or death at 48 weeks and this figure was 16% for the early 
ART group.18 This further revealed that the earlier ART was initiated, there were 
improved TB treatment outcomes. 
In Lesotho in 2012, a study conducted on 134 confirmed MDR-TB patients with 94 
(70%) being co-infected with HIV, showed that the time to death for patients not on 
ART was notably shorter than that of those on ART. 19 Out of 134 HIV confirmed 
MDR-TB patients, 83(62%) were cured or completed treatment, 46(34%) died, 3(2%) 
transferred, 1(1%) defaulted and 1(1%) failed treatment. 19 Among the 94 (70%) 
patients with HIV co-infection, 53% were already on (ART) before MDR-TB treatment  
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and 43% started ART a median of 16 days after the start of the MDR-TB regimen. 
Among HIV co-infected patients who died, those who had not started ART had a 
shorter median time to death (80 days vs. 138 days, p = 0.065). 19 The importance of 
early initiation of ART was highlighted, even though PLHIV severely 
immunosuppressed may take longer to show a benefit from ART. 19 
In Cape Town in 2005, a study reported that the frequency of extra-pulmonary 
disease in people living with HIV associated TB started early on ART was reduced.20 
There were however, indications that paradoxical reactions were associated with 
early initiation of ART in people living with HIV associated TB.20 These paradoxical 
reactions were significantly associated with starting ART within six weeks after 
beginning TB treatment (p= 0.03).21 
2.6 Changes in CD4 count and viral load  
Changes have been noted in the CD4 count and viral load depending on stage of 
initiation of ART in people living with HIV associated TB. A study conducted in Cape 
Town in 2005 revealed that early initiation of ART in people living with HIV associated 
TB has been associated with viral load suppression which then leads to reconstitution 
of the immune system. 20 The study showed that the CD4 cell count for patients who 
were diagnosed with TB who had already started on ART was significantly higher 
than the level of CD4 count for patients who did not receive ART at the time their TB 
was diagnosed. This finding suggests that substantial restoration of CD4 cell 




2.7 Challenges of early initiation of ART  
People living with HIV associated TB may not have access to TB and HIV services 
for a variety of reasons that may differ from country to country. In a rural district in 
Malawi, acceptance of ART was low and was associated with scarce availability of 
transport and high transport costs to the hospital. Hospitals providing ART at the time 
were centralized.22 The following factors were also reported as hindrances to early 
initiation of ART in HIV associated TB: 
• ART is deferred until the continuation phase of tuberculosis treatment when 
the sickest patients might have died and survivors feel well enough not to start 
ART. 
• In the continuation phase, tuberculosis treatment was decentralized whereas 
ART often still remained centralized, a negative factor requiring several visits 
to different facilities to obtain antiretroviral medications. 
• Tuberculosis and ART services operate in a vertical manner in many health 
facilities, making access to ART difficult for patients con-infected with 
tuberculosis. 
• There are specific clinical challenges of combined TB and ART management, 
including the following: optimum time to start ART; how best to combine 
rifampicin-containing regimens with first-line and second-line ART; 
consideration of rifabutin instead of rifampicin; management of immune 
reconstitution disease; and the role of isoniazid preventive therapy after 
completion of tuberculosis treatment. 
• Inadequate empowerment of patients and community groups on the benefits of 
combined ART and tuberculosis treatment.23  
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In Lesotho, access to health care is limited because of poor health infrastructure 
which is inadequately staffed; this has been a problem especially for PLHIV and TB.24 
In some cases, patients would go to the dilapidated health centers, wait on the queue 
for the whole day and go home without obtaining healthcare. 24 However, in 2015 the 
Millennium Challenge Corporation (MCC) through its partnership with Millennium 
Challenge Account – Lesotho (MCA) has intervened by addressing health sector 
challenges through $122,000 million investment in health infrastructure and health 
system. 24   
A study conducted in Lesotho in 2009 among 13 243 PLHIV enrolled in HIV care 
between 2006 and 2008, showed that the government of Lesotho was committed to 
addressing HIV/AIDS and TB but there are persisting health care delivery problems 
including major health resource constraints. 25 There is a dire shortage of health 
professionals Lesotho has just 5 doctors and 62 nurses per 100 000 inhabitants as 
compared South Africa with 74 doctors and 393 doctors per 100 000 inhabitants. 25 
2.8 Summary of the chapter 
The literature review showed that there exists an association between survival and 
early initiation of ART in PLHIV associated TB. CD4 count and viral load also showed 
improvements where ART was initiated early. There were however, adverse effects 
such as development of Immune Reconstitution Inflammatory Syndrome (IRIS) in 
some people living with HIV associated TB who were started early on ART. In some 
settings, challenges to  access of ART to people living with HIV associated TB 
included  high transport costs to hospitals, long distances to clinics, long queues at 
hospitals which discourage or deter patients to seek appropriate treatment. There is 
however strong evidence that countries should commence PLHIV associated TB 
early on ART. 
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3 CHAPTER THREE: RESEARCH METHODS 
In this section, the research methods employed in this study to show whether early 
initiation of ART in adults living with HIV associated TB in Lesotho in 2012 have 
proved effective or not will be described. The chapter includes information on the 
study setting, study design, target population, study population, sampling and data 
processing and analysis.  
3.1 Study setting 
The study was conducted in three selected hospitals in Lesotho, namely Berea, 
Ntsekhe and Scott hospitalsb. 
3.2 Study design 
An observational, analytic cross-sectional study design was used. 
3.3 Target population 
The target population is focused on adults living with HIV associated TB and can be 
generalized to similar populations from other comparable hospitals and areas 
throughout Lesotho. 
                                            
b Berea Hospital is a government hospital which serves about 251 169 people in its catchment area. It 
has an integrated TB and HIV programme where people are served under one roof. Ntsekhe Hospital 
is also a government hospital which serves about 175 497 people in its catchment area. It also offers 
TB and HIV services under one roof. On the other hand, Scott is a Christian Hospital Association of 
Lesotho (CHAL) hospital which serves about 13 275 people in its catchment area. It also has an 
integrated TB and HIV programme where people living with HIV and TB are served under one roof. 
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3.4 Study population 
The study population consisted of adults living with HIV associated drug-sensitive TB 
(both pulmonary and extra-pulmonary) and who commenced TB treatment in Lesotho 
at Berea, Ntsekhe and Scott Hospitals from January to March (first quarter) 2012.c 
The plan was to assess treatment outcomes of a cohort of people living with HIV 
associated TB one year after all the participants had commenced TB therapy and had 
completed therapy in April 2013, since all such patients would have had their 
treatment outcomes and mortality recorded. Consequently, the effectiveness of 
therapy could be measured. However, there were delays in finalizing the protocol. 
This meant that the evaluation of participants was only done in July 2013, but on the 
same cohort of people living with HIV associated TB proposed in the protocol. 
3.4.1 Inclusion / exclusion criteria 
Inclusion and exclusion criteria were considered in this study. 
3.4.1.1 Inclusion criteria 
All people aged 15 years and above of both sexes were included in this study as they 
are considered to be ‘adults’ in Lesotho. The inclusion criteria included all those living 
with HIV at the commencement of TB treatment, but who were not already on ART 
                                            
c Patients with both pulmonary and extra-pulmonary TB were included, but those with multi-drug 
resistant (MDR-TB) and extensive-drug resistant (XDR-TB) TB were excluded, as they are not enrolled 
into the TB programme at district level in Lesotho. Patients with drug resistant TB receive care from 
the XDR-TB and MDR-TB treatment centre located in Maseru the capital of Lesotho where all such 
patients are managed. 
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when diagnosed with TB. These included adults started on TB treatment who had 
come to the hospital with an already known HIV positive status as well as those who 
tested positive at the commencement of TB treatment. 
3.4.1.2 Exclusion criteria 
The exclusion criteria included all people living with HIV associated TB who 
commenced TB treatment and were already on ART when commencing TB 
treatment. In addition, patients who were ‘Transferred Out’ to another TB care centre, 
specifically patients with MDR-TB and XDR-TB strains of the disease were excluded 
from the study population.   
3.5 Study sample 
The study sample comprised 247 patients with HIV associated TB, selected from 
three out of the 17 hospitals in Lesotho. There were to be 70 participants from Berea, 
64 from Scott and 113 from Ntsekhe Hospital. 
3.5.1 Size of sample 
A software package called Survey Random Calculator provided by Custom Insight 
was used to determine the sample size required to give an estimate with 95% 
confidence interval and 5% margin of error. The study sample size required was 245. 
The study population comprised 302 people living with HIV associated TB who 
qualified to participate in the study recorded in the TB registers during the study 
period, of which 75 were identified at Berea Hospital, 72 at Scott Hospital and 155 
from Ntsekhe Hospital. The proportional study sample size from each hospital was 
determined to be 63 from Berea Hospital, 72 for Scott Hospital and 110 for Ntsekhe 
Hospital. However, during data collection, the Scott Hospital study sample size 
dropped from 72 to 64 as it was found at the time of data collection that some 
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patients had been ‘double entered’ into the hospital TB register. The number of 
patients obtained from Berea and Ntsekhe was increased from 63 to 70 and 110 to 
113 respectively to compensate for fewer patients being available from Scott Hospital 
giving a total of 247 patients that comprised the study sample.  
3.5.2 Method of selecting sample 
A multi-stage stratified random sampling process was used. Lesotho has 17 hospitals 
(seven belong to the Christian Health Association for Lesotho (CHAL) and ten 
government hospitals) and these were the primary sampling units. In order to obtain a 
representative sample, the first stage of this process involved selecting three of the 
17 (18%) hospitals randomly without replacement from a list of all hospitals (both 
government and CHAL).  
The second stage of sample selection occurred at the hospital level, where all TB 
patients who commenced TB therapy during the review period (January to March 
2012) were selected from the TB register. The third stage of sample selection was 
where 70 participants were selected from Berea, 64 from Scott and 113 from Ntsekhe 
Hospital using simple random sampling without replacement.  
3.6 Data sources 
The TB registers kept at the hospitals were used as the primary source of data for 
each participant included in the study sample. Where possible, TB treatment cards 
which were available at the hospital TB clinic were used to verify the data from the TB 
register and obtain data missing from the TB registers.d 
                                            
d In Lesotho, TB patients have 2 treatment cards opened once they are commenced on TB treatment; 
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3.6.1 Measurement instruments / Data collection techniques 
A data collation sheet was completed by the researcher to enter the data required 
from each of the participants for the study including type of TB, TB treatment 
regimen, timing of ART initiation, CD4 count results and the TB treatment outcomes. 
e  
3.7 Measures to ensure validity 
In order to ensure validity in this study, internal and external bias was reduced as far 
as possible.  
3.8 Internal validity 
The internal validity was improved by reducing selection and information bias. 
3.8.1 Selection bias 
Selection bias was reduced by clearly defining the study population, giving careful 
attention to sampling and proper identification of people living with HIV associated TB 
who started ART early and those who had begun it late. 
                                                                                                                                         
one is left at the facility and the other one is kept by the patient. Both cards are updated every time the 
patients come to the facility for care.  
e Viral load has been excluded as a variable because in Lesotho, the test is done only for serious 
cases, due to the cost of the test and its affordability in Lesotho. 
22 
 
3.8.2 Information bias   
Information bias was reduced by using standardized measures for each variable. At 
each hospital, the same CD4 cell count machine was used for all patients, the same 
weight scale was used and TB and HIV treatment provided was the same, depending 
upon the needs of all patients and given according to the Lesotho Standard 
Treatment Guidelines. The process of standardising the data collation was assisted 
by maintaining a data collation form and having this collected and collated by one 
person, namely the principal investigator. 
3.9 External validity / Generalisability 
In this study, adults living with HIV associated TB of both sexes were included in the 
study population. This was done so that the results obtained could be generalized to 
other hospitals and areas in Lesotho with a similar population and environmental 
conditions.  
3.10 Pilot study 
The initial plan was to conduct a pilot study prior to the actual research study but the 
researcher was restricted by time factors and could therefore not undertake a pilot 
study.   
3.11 List of variables  
There were specific variables that were measured in this study. The TB outcome 
variables collected were the standard TB treatment outcomes used in Lesotho and 
recommended by the WHO. The exposure variables used concerns the question of 
whether the patient received early initiation of ART (less than 4 weeks from 
commencing TB therapy), late initiation of ART (four or more weeks from 
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commencing TB therapy) or no ART. These variables were used as the purpose of 
the study was to assess the effectiveness of the stage of ART initiation in those 
patients living with HIV associated TB on their TB outcomes.   
3.12 Plan for data collection 
Data was collected in July 2013 at the time that all participants had completed their 
TB treatment and the measurable outcomes were available and would have been 
recorded in the relevant hospital TB registers. 
3.13 Plan for data handling/processing 
Clear procedures were followed in this study to ensure proper data handling. 
Consequently, data collected and used in this study was accessed by the researcher 
only, in order to ensure confidentiality. The researcher captured data into the 
computer that only authorized personnel possessed access to even during statistical 
processing of the data. Moreover, participants’ names were not captured; instead, 
codes were given to each participant for confidentiality reasons. Different letters were 
used to identify patients according to their hospitals. Participants from Scott Hospital 
had their code starting with “S”, those from Berea Hospital started with “B” and lastly 
those from Ntsekhe Hospital had their code starting with “M”.  
3.14 Statistical methods 
Statistical methods used in this study were descriptive and analytic.     
3.14.1 Descriptive statistics 
Descriptive statistics methods were used to organise, summarise and describe data. 
In this study, categorical data was summarised using appropriate frequency 
distribution tables and graphs.  
24 
 
3.14.2 Analytic statistics 
Multivariable models were used to draw inferential conclusions on the data. These 
showed how the outcome was associated with the exposure variables being 
measured after controlling for confounding variables. SPSS was the statistical soft-
ware package used to calculate measures of associations and the chi-squared test.  
3.15 List of possible confounding factors  
The possible confounders in this study included age, sex, TB site (pulmonary or 
extra-pulmonary), hospital ownership and treatment category. To control for 
confounding, stratification and multivariable models were considered for all variables 
that were likely to complicate the estimation of the measures of association between 
exposures and outcomes.    
Each predictor was tested bivariately against the TB outcomes using a logistic 
regression. Variables significant at p<0.2 level were selected for entry into the final 
multivariable model. The link test was also performed to check model specification. 
Multivariable model fit was assessed using the Hosmer and Lemeshow's goodness of 
fit statistic. A classification table was also produced relating observed versus 
predicted outcomes from the model, i.e. predictive power. Multicollinearity between 
predictors was also assessed as this factor can erroneously affect the coefficient 
values. This was assessed using the variance inflation factor (VIF). As a general rule 
of thumb, the VIF should not exceed 10, though some sources of literature suggest 
this cut-off should be lower i.e. 5. 
3.16 List of associations to be measured 
The measures of association that were calculated in this study to determine whether 
there was an association between the exposed and the un-exposed variables relative 
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to the outcome were prevalence ratio and odds ratio. These were measured to 
assess the exposure and outcome relationship in the variables being evaluated and 
to check the strength of association between the variables. The exposure variables 
evaluated were hospital, type of TB, site of TB, CD4 count cell/mm3, age, sex and 
time of ART initiation. 
3.17 Ethical considerations 
An expedited ethical review process was followed as this study involved processing 
and analysing data collected from patient records. There was no direct patient 
contact.   
3.17.1 Institutional ethical review board 
Lesotho has a Research Coordinating Unit (RCU) that needs to give approval before 
any research is commenced. Thus, the Lesotho RCU was consulted prior to this 
study, being carried out and approval was granted. Expedited ethical approval was 
also obtained from the College of Health Sciences, Biomedical Research Ethics 
Committee at the University of KwaZulu-Natal (BREC No.: BE300/12). 
3.17.2 Permissions 
The study obtained data from the TB registers in the hospitals and prior to extracting 
the data from the TB registers gate-permission was obtained the hospital 
management.  
3.17.3 Informed consent 
Adults living with HIV associated TB being studied did not have a direct benefit from 
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this study. Thus, it was not necessary to obtain informed consent and information 
from the subjects.f 
3.18 Summary of the chapter   
This study used an observational analytic cross-sectional design and was conducted 
in three hospitals in Lesotho namely Berea, Ntsekhe and Scott Hospitals. The target 
population would be adults living with HIV associated TB in similar hospital to those 
selected in Lesotho. The study sample comprised 247 participants and TB registers 
were used to obtain data using a custom designed data collection tool. The statistical 
software utilised to process and analyse data was SPSS. Associations measured 
included prevalence and odds ratios. Regarding ethical considerations, the Lesotho 
Research Coordinating Unit was consulted and approval was granted. The College of 
Health Sciences, Biomedical Research Ethics Committee at the University of 
KwaZulu-Natal granted an expedited ethical approval for the study as well. Lastly, 
permission was sought from the management at three hospitals to conduct the study. 
  
                                            
f Participants did not have a direct benefit in respect of the flat that, the researcher was interested in 
the outcomes of TB patients and only those enrolled after the study is completed will benefit because 
the recommendations will be shared with the Lesotho MOHSW. Data was collected from hospital 




4 CHAPTER FOUR: RESULTS 
4.1 Introduction 
In this chapter of the dissertation, I will present the results of the study. In the first 
section, the study sample characteristics are described. In the second section timing 
of antiretroviral therapy is presented. The TB outcomes are presented in the third and 
fourth section of the results chapter. In the third section, associations between the 
standard WHO TB outcomes and the timing of ART commencement are assessed 
using prevalence ratios. In the fourth section the TB outcomes are dichotomised as 
‘successful’ or not and using logistic regression a multivariable model is developed. 
4.2 The study sample 
There were 247 participants living with HIV associated TB who were enrolled in the 
study of which, 70 (28%) were from Berea Hospital, 64 (26%) from Scott Hospital and 
113 (46%) from Ntsekhe Hospital. Slightly more than half (54%) of participants were 
males. There were more males (42/70 - 60%: 95% Confidence Interval (CI): 48 to 71) 
in Berea Hospital compared to the other two hospitals. The difference was not 
statistically significant (p = 0.22). Only in Ntsekhe Hospital were there recorded more 
females than males. The difference was not statistically significant (p = 0.37) (Table 
1). 
A slightly higher proportion of females (109/114 - 96%; 95% CI: 90 to 98) comprised 
of new TB cases compared to males (120/133 - 90%; 95% CI: 84 to 94). There was a 
2.4 times increased risk of females being new cases compared to males (Odds Ratio 
(OR) 2.4; 95%CI: 0.8 to 6.8) but this factor was not statistically significant (p = 0.11) 




Regarding site of disease and gender, males are 1.6 more likely to get pulmonary TB 
compared to females. (OR 1.6; 95% CI: 0.7 to 4.0). This is confirmed by results which 
further show that it is more likely for males (124/133 - 93%: 95% CI: 87 to 97) to have 
pulmonary TB than females (102/114 - 90%; 95% CI: 82 to 94). The association was 
not statistically significant (p = 0.29) (Table 1).  
Only 86 (65%) males and 86 (75%) females had a known CD4 count result recorded 
in the TB register. In the participants who had a result a similar proportion of males 
(49/86 - 57%; 95% CI: 46 to 68) recorded a CD4 count below 200 cell/mm3 to 
females (48/86 - 56%; 95% CI: 45 to 66) (Table 1). 
Overall, only 180 of the 247 (73%) people with HIV associated TB had commenced 
antiretroviral therapy. A greater proportion of females (87/114 - 76%; 95% CI: 67 to 
84) than males (93/133 - 70%; 95% CI: 61 to 77) were on ART. Females were more 
likely to have been initiated on ART late (more than 4 weeks after commencing TB 
therapy) (49/114 - 43%; 95% CI: 34 to 53) compared to males (51/133 - 38%; 95% 




Table 1: Gender of adult patients living with HIV associated TB in three 
hospitals, by type and site of TB, CD4 count, age and stage ART was initiated 
in Lesotho, 2012. 
  Males n (%) 
95%CI 




Hospital Berea 42 (60.0%)  
47.6 to 71.3 
28 (40.0%)  
28.7 to 52.4 
70  
(28.3%) 
 Scott 37 (57.8%)  
44.8 to 69.8 
27 (42.2%) 
30.2 to 55.2 
64  
(25.9%) 
 Ntsekhe 54 (47.8%)  
38.4 to 57.5 
59 (52.2%)  
42.7 to 61.6 
113  
(45.7%) 
Type TB New 120 (90.2%) 
83.6 to 94.5 
109 (95.6%)  
89.6 to 98.4 
229  
(92.7%) 
 Other 13 (9.8%) 
5.5 to 16.5 
5 (4.4%)  
1.6 to 10.4 
18  
(7.3%) 
Site of TB Pulmonary  124 (93.2%) 
87.2 to 96.7 
102 (89.5%) 






3.3 to 12.8 
12 (10.5%) 
 5.8 to 18.0 
21  
(8.5%) 
CD 4 Count 
cell/mm3 
Known CD4 86 (64.7%) 
55.8 to 72.6 
86 (75.4%) 
66.3 to 82.8 
172  
(69.6%) 
           <200 49 (57.0 %) 
45.9 to 67.5  
48 (55.8%) 
44.7 to 66.4 
97  
(39.3%) 
            200+ 37 (43.0%) 
32.5 to 54.1 
38 (44.2 %) 
 33.6 to 55.3 
34  
(13.8%) 
 Unknown CD4 
 
47 (35.3%) 
27.4 to 44.2 
28 (24.6%) 
17.2 to 33.7 
75  
(30.4%) 
Age  < 30 years 31 (23.3%) 
16.6 to 31.6 
43 (37.7%) 
29.0 to 47.3 
74 
(30.0%) 
 30 + years 102 (76.7%) 
68.4 to 83.4 
71 (62.3) 






weeks   
42 (31.6%) 
24.0 to 40.3 
38 (33.3%) 
25.0 to 42.9 
80  
(32.4%) 
 Late >4 weeks  51 (38.3%) 
30.2 to 47.2 
49 (43.0%) 
33.9 to 52.6 
100  
(40.5%) 
 No Treatment 40 (30.1%) 
22.6 to 38.7 
27 (23.7%) 
16.4 to 32.7 
67  
(27.1%) 
 Total 133 (53.8%)  
47.4 to 60.2 
114 (46.2%) 







Figure 2: Age and gender of adults living with HIV associated TB in three 
hospitals Lesotho, 2012  
In this study, all participants were aged 15 years and above. A greater proportion 
(43/114 - 38%; 95% CI: 29 to 47) of females were less than 30 years of age 
compared to 31 of 133 (23%; 95% CI: 16 to 31) who were males (Figure 2). This 
difference was statistically significant (p < 0.05). This gender ratio was reversed in 
those older than 30 years, with males comprising 72% (96/133 - 95% CI: 64 to 79) 
and females 58% (66/114 - 95% CI: 48 to 67).  
Of the 247 participants, 229 (93%) received the basic and first line Category 1 
treatment regimen. All of these patients had newly diagnosed TB. The 18 (7%) who 
were received the Category 2 regimen were all patients with HIV associated TB who 











































Table 2: Treatment category and patient type for adults living with HIV 
associated TB in Lesotho, 2012.  
Treatment 
Category 
Patient Type Total 
 New Other 
Category 1 229 (100.0%) 0 (0.0%) 229 (92.7%) 
Category 2 0 (0.0%) 18 (100.0%) 18 (7.3%) 
Total 229 (100.0%) 18 (100.0%) 247 (100.0%) 
 
4.3 Timing of antiretroviral therapy initiation 
About 31% of those with HIV associated TB who did not commence ART were less 
than 30 years of age (23/74 - 31%; 95% CI: 21 to 43). This factor was not statistically 
significant (p = 0.20). There was no statistical difference in the proportion who 
initiated ART early or late according to age, the prevalence ratio being 0.9 in early 
initiators (95%CI: 0.6 to 1.5), 1.3 in late initiators (95% CI: 0.8 to 2.0) in those less 
than 30 years and 1.3 in early initiators (95% CI: 0.8 to 12.2) and 1.6 in late initiators 




Table 3: Early and late ART initiators by age for adults with HIV associated TB 
in three hospitals in Lesotho, 2012. 

















 21 (28.4%) 
18.8 to 40.2 
0.9 
(0.6 to 1.5) 
59 (34.1%) 
27.2 to 41.7 
1.3  
(0.8 to 2.2) 
80  
32.4% 
Late    
Initiation 
30 (40.5%) 
29.3 to 51.7 
1.3 
(0.8 to 2.0) 
70 (40.5%) 
33.2 to 48.2 
1.6  
(1.04 to 2.5)  
100  
40.5% 
No ART 23 (31.1%) 
21.1 to 43.0 
Reference 44 (25.4%) 
19.2 to 32.7 
Reference  67  
27.1% 
Total 74 (100.0%)  173 (100.0%)  247 
100.0 
 
Ninety seven participants (97/247 - 39%; 95% CI: 33 to 46) recorded CD4 count less 
than 200 cell/mm3 and 75 a CD4 count 200 cell/mm3 and above (75/247 - 30%; 95% 
CI: 25 to 37) or had an unknown CD4 count (75/247 - 30%; 95% CI: 25 to 37). The 
difference was not statistically significant (p < 0.25) (Table 4).  
Most (48/67; 72%; 95% CI: 59 to 82) of those who did not have a CD4 count were not 
on ART.  
Participants with a CD4 count less than 200 cell/mm3 (PR 6.5; 95% CI: 3.0 to 14.4) 
were more likely to be initiated early on ART compared to those with CD4 of 200 
cell/mm3 and above and those with no CD4 count (PR 1.7; 95% CI: 0.1 to 3.1 and PR 
                                            
g Early initiation of ART refers to participants initiated on ART four or less weeks after commencing TB 
treatment and late initiation were those started late more than four weeks 
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0.1; 95% CI: 0.4 to 0.2 respectively). Similarly, those with CD4 count less than 200 
cell/mm3 were 4.9 times (PR 4.9; 95% CI: 2.2 to 10.6) of being initiated late on ART 
compared to those with CD4 of 200 cell/mm3 and above and those with no CD4 count 
(PR 1.8; 95% CI: 1.0 to 3.2 and PR 0.3; 95% CI: 0.2 to 04 respectively) (Table 4). 
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Table4: Early and late ART initiators by CD4 count for adults with HIV associated TB in three hospitals in Lesotho 
in 2012. 
      
ART 
Initiation 




















47.2 to 69.5  
6.5  
(3.0 to 14.4) 
27 (33.7%) 
23.8 to 45.3 
1.7  
(0.1 to 3.1) 
6 (7.5%)  
3.1 to 16.2 
0.1  






34.2 to 54.3 
4.9  
(2.2 to 10.6) 
35 (35.0%) 
25.9 to 45.3  
1.8  
(1.0 to 3.2) 
21 (21.0%) 
13.8 to 30.5 
0.3  
(0.2 to 0.4) 
100  
40.5% 
No ART 6 (9.0%) 
3.7 to 19.2 
Reference 13 (19.4%) 
11.1 to 31.2  
Reference 48 (71.6%) 
59.1 to 81.7  
Reference 67  
27.1% 
Total 97 (39.2%) 
 33.2 to 45.7 
 75 (30.4%) 
24.8 to 36.6 
 75 (30.4%) 
24.8 to 36.6 
 247 
100.0% 
                                            
h Early initiation of ART refers to participants initiated on ART four or less weeks after commencing TB treatment and late initiation were those 
started late more than four weeks 
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4.4 TB outcomes depending on stage of antiretroviral therapy initiation.  
The outcomes were calculated for each of the WHO standard TB outcome indicators 
(Table 3). In this section, the association between each outcome and stage of ART 
initiation was calculated as prevalence ratios. The cure and completed treatment 
outcomes were both better in those who commenced ART late (prevalence ratio (PR) 
3.3; 95% CI: 1.9 to 5.7 and PR 2.6; 95% CI: 1.5 to 4.8 respectively) compared to the 
early initiators (PR 1.7; 95% CI: 0.9 to 3.2 and PR 2.5; 95% CI: 1.3 to 4.5 respectively) 
relative to those not commenced on ART.  
When the cure and completed outcomes were aggregated as “successful” the outcomes 
were also both better in those who commenced ART late (PR 1.9; 95% CI: 1.4 to 2.5 
compared to the early initiators (PR 1.9; 95% CI: 0.9 to 3.2) relative to those not 
commenced on ART. The deaths and defaulter outcomes were both much worse in 
those who did not have any ART relative to both late (PR 0.4; 95% CI: 0.3 to 0.6 and 
PR 0.5; 95% CI: 0.3 to 0.8) and early initiators (PR 0.3; 95% CI: 0.2 to 0.5 and PR 0.4; 




Table5: TB treatment outcomes and prevalence ratios (PR) for different stages of ART initiation in people living 
with HIV associated TB in three hospitals in Lesotho, 2012  
    TB Treatment Outcomes (WHO)    
ART 
Initiation 




































































































No ART 7 
16.6% 


























Successful Outcome = Cured +Completed treatment. TOTAL = Successful + Died + Defaulted + Failed
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4.5 Factors associated with TB treatment outcomes 
In this section, the factors associated with TB treatment outcomes were analysed using 
logistic regression and the unadjusted and adjusted results presented. Those patients 
with HIV associated TB who were cured and completed were aggregated together as 
having a ‘successful’ outcome.  
4.5.1 Unadjusted findings   
Ages of those with HIV associated TB, which hospital they were being managed at, 
gender, site of TB, type of TB and CD4 count were the factors (independent variables) 
analysed and the outcome was ‘successful’ (cured and completed) TB treatment.  
Participants aged below 30 years were 1.1 times more likely to have successful TB 
treatment outcome (OR 1.1:  95% CI: 0.6 to 2.1) than those aged 30 years and above. 
The difference was not statistically significant (p=0.696) (Table 6).  
Participants with HIV associated TB from Berea Hospital had less chances of having 
successful TB outcomes (OR 0.5: 95%CI: 0.3 to 1.0) relative to those from Scott 
Hospital and the difference was marginally statistically significant (p=0.063). On the 
other hand, HIV associated TB participants from Ntsekhe Hospital were 0.9 times less 
likely to obtain successful TB outcomes (OR: 0.9: 95% CI: 0.4 to 2.0) and the difference 
was not statistically significant (p=0.741) (Table 6). 
Slightly more males (97/133; 73%; 95% CI: 64 to 80) had successful TB outcomes 
compared to females (79/114; 69%; 95% CI: 60 to 77). The unadjusted OR of 0.8 (95% 
CI: 0.5 to 1.5) indicated that females were 0.8 times less likely to have successful TB 
outcomes than males and the difference was not statistically significant (p=0.529) 
(Table 6).   
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Those with extra pulmonary TB were 1.8 times more likely (OR 1.8: 95% CI: 0.6 to 5.5) 
to have a successful TB outcomes. The difference was not statistically significant 
(p=0.310). Additionally, patients who were taking TB therapy for the first time were 0.6 
times less likely (OR 0.6: 95% CI: 0.2 to 1.6) to have successful TB outcomes than 
those repeating a course of TB therapy for whatever cause. The difference was not 
statistically significant (p=0.327) (Table 6). 
Not all the sample had a record of having had a CD4 count. Successful TB outcomes 
were not dependent on CD4 count. Participants with a CD4 count less than 200 
cell/mm3 had less chances of having successful TB outcomes (OR: 0.9: 95% CI: 0.2 to 
1.6) relative to those with no CD4 count  and the difference was statistically significant 
(p=0.011). Similarly, those with a CD4 count of 200 cell/mm3 and above were 0.8 times 
less likely to obtain successful TB outcomes (OR 0.8 95% CI: 0.4 to 1.6) and the 
difference was not statistically significant (p=0.493) (Table 6). 
Out of 247 adults living with HIV associated TB, 80 (32%) were started on ART early (4 
weeks or less), 100 (41%) were started late (after 4 weeks) and 67 (27%) received no 
ART at all. The unadjusted results show that early initiators were 6 times more likely to 
have a successful TB outcome (OR 6.2: 95%CI: 3.7 to 27.5) relative to the group who 
had no ART. This difference was statistically significant (p<0.001) (Table 6). 
Interestingly those who commenced ART late also had a six times more likely to have a 
successful TB outcome (OR 5.6: 95% CI: 2.8 to 11.2) relative to the group who had no 
ART.i 
                                            
i The Odds Ratio overestimates the association between timing of ART initiation and successful outcome. 
The OR was 6.2 in early initiators and 5.6 in late initiators relative to those who did not commence ART. 
The prevalence ratio was 1.91 and 1.87 for the same exposures and outcomes. The Odds Ratio is 
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4.5.2 Adjusted findings 
After the bivariate regression, some predictors, namely hospital, CD4 count and stage 
when initiated on ART remained significant and therefore were included into the 
multivariable analysis. However, age and sex by virtue of being confounders were also 
included into the multivariable model even though they were not significant. In the final 
model, hospital (OR 0.4: 95% CI: 0.2 to 1.0) and stage when initiated on ART (OR 10.1: 
95% CI: 3.7 to 27.5) were the two predictors that remained statistically significant as 
revealed by the p-values p=0.040 and p<0.001 respectively. Nonetheless, age and sex 
were closer to being significant in the multivariable analysis with p=0.212 and p=0.288 
respectively than in the bivariate analysis with p=0.696 and 0.529 respectively. 
Regarding age, the p-value dropped from p= 0.696 to p=0.212 while the p-value for sex 
moved from p=0.529 to p=0.288 (Table 6). 
  
                                                                                                                                             
overestimated when the occurrence of the outcome variable is greater than 0.1. It is however much easier 
to calculate the adjusted Odds Ratio using logistic regression, and this finding is commonly reported in 
cross-sectional studies where prevalence is the measure of disease occurrence measured.  
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Table 6: Successful TB outcomes by stage of ART Initiation, hospital, age, sex, CD4 count, site of TB and type of 
TB & AIDS service for adults living with HIV associated TB in three hospitals in Lesotho, 2012. 
Predictor n/N 
Unadjusted Adjusted  
Odd 
Ratio 
95% CI  P value Odd Ratio 95% CI  P value 
Age:   30+ years 122/173 1 (Ref.)       
         <30 years 54/74 1.13 0.61 to 2.07 0.696 0.64 0.32 to 1.29 0.212 
Hospital: Scott 50/64 1 (Ref.)       
                Ntsekhe 73/113 0.87 0.39 to 1.95 0.741 0.44 0.20 to 0.96 0.040 
                Berea 53/70 0.51 0.25 to 1.04 0.063 0.61 0.24 to 1.61 0.333 
Sex:        Male 97/133 1 (Ref.)       
               Female 79/114 0.84 0.48 to 1.46 0.529 1.41 0.75 to 2.65 0.288 
Site: PulmonaryTB 159/226 1 (Ref.)       
         Extra-PTB 17/21 1.79 0.58 to 5.52 0.310 - - - - 
Type: Repeat TB 11/18 1 (Ref.)       
           New TB 165/229 0.61 0.23 to 1.64 0.327 - - - - 
CD4: Unknown 47/75 1 (Ref.)       
         <200 78/97 0.89 0.21 to 1.59 0.011 0.76 0.28 to 2.01 0.578 
200+ 54/75 0.79 0.40 0.493 0.49 0.19 to 1.25 0.136 
Stage ART initiated        
      No ART  29/67 1 (Ref.)       
      Early (<4 week) 66/80 6.18 2.91 to 13.1 0.000 10.07 3.69 to 27.48 0.000 




4.6 Summary of the chapter  
In this study the effectiveness of TB outcomes in patients living with HIV associated TB 
in Lesotho was assessed. There was duplication of records found at one hospital. Only 
70% had a CD4 count. About 1/3 of the participants had no ART, 1/3 had early ART and 
1/3 had late ART. Those not on ART were much worse off. There was no difference 




5 CHAPTER FIVE: DISCUSSION 
5.1 Introduction 
In this chapter the results obtained in the study will be discussed in relation to the 
existing literature on the topic of TB outcomes in relation to those living with HIV 
associated TB in Lesotho in 2013. The discussion contains five sub-sections, namely 
the study sample; factors associated with timing of antiretroviral therapy initiation, TB 
outcomes depending on the stage of antiretroviral therapy initiation, factors associated 
with treatment outcomes, to get the with two sub headings, unadjusted findings and 
adjusted findings and, finally, the limitations.  
5.2 The study sample 
There were slightly more males (54%) than females (46%) living with HIV associated TB 
in this study. Females were however generally younger than their male counterparts. A 
study conducted in Hong Kong in 2013 evaluating the optimal time for initiating ART in 
260 patients with HIV associated TB had 228 (88%) males and 32 (12%) females and 
the average age for males was 40 years, while that of females was 34 years. 17 Those 
with HIV associated TB in low income countries such as Lesotho have a very different 
demographic profile than in high income countries. Our participants confirmed much to 
that of the participants in the SAPiT trial conducted in Durban in 2010, which reported 
that gender distribution of their 642 participants was equal.27  
It is probable that the demographic profile at Ntsekhe Hospital, which recorded more 
females than the other two hospitals could have resulted from a Prevention of Mother-
to-Child programme at the hospital. Most females in this hospital are routinely HIV 
tested and those who test positive at the antenatal clinic were referred to the ART clinic 
unlike the prevailing in other hospitals where relatively few women are HIV tested. The 
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essential fact is that, the two hospitals, namely Berea and Scott, are not the only 
hospitals in their districts. This explains why some women go elsewhere for antenatal 
services. 
Out of 229 new TB cases, more than half (52%) were males. Although a study 
conducted in Pakistan revealed a contrary situation where there were more new female 
TB cases being notified.28 This study however, showed results similar to most countries, 
including America, nations in South-East Asia and in Europe, the opposite phenomenon 
is observed where more male cases were notified with TB. 28 
All the newly diagnosed TB patients were receiving treatment that is the recommended 
first line TB therapy type and those who had repeat TB infection were on the standard 
second-line therapy. The practice in Lesotho is similar to what is being done in South 
Africa. 29 The 2009 National Tuberculosis Management Guidelines of the Department of 
Health in South Africa recommended that the newly diagnosed (treatment naïve) TB 
patients should be on standard first-line TB therapy. 29 The guidelines further 
recommend that those with TB who are repeating treatment for TB should be on a 
standard second-line therapy regimen, but that sputum should be sent for culture and 
drug susceptibility testing. 29 
Slightly more of the male PLHIV (55%) in this study had HIV associated pulmonary TB. 
This is different from the nature of that found in a study conducted in Uganda in 2002 
where more females (109 out of 214; 51%) were reported to have PTB. 30  
A disappointing factor concerning the matters that only (70%) of the participants in this 
study had a recorded a CD4 count. Of those who had a CD4 count result, 44% had a 
CD4 count greater than 200 cell/mm3. In Durban in 2012, 1% of HIV associated TB 
patients had no CD4 count, and in those who reported a CD4 count, it was less than 50 
cell/mm3 in 48%, 51 to 100 in 26%, 101 to -200 in 24% and greater than 200 cell/mm3 in 
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only 3%.31 PLHIV in LIC are diagnosed with HIV associated TB, they are sicker and 
their CD4 counts are found to have CD4 count below 200 cell/mm3. 31 
There were no significant differences in age between male (54%) and female (46%) 
participants in our study. There were more PLHIV in Lesotho aged above 30 years. A 
study in Durban in 2012 demonstrated a similar situation where, in 458 patients with 
HIV associated TB, the median age was calculated as 35 years and the interquartile 
range was 30 to 42 years. 31 
More males (52%) were on ART. Such a phenomenon is similar to that which was 
observed in a study of 69 PLHIV associated TB conducted in Iran in 2009, where more 
males (68%) were started on ART than females. 9 The results obtained were similar to 
what was found in Durban in 2012. 31 The study had 458 participants, who weren't 
divided into three (3) groups, namely the immediate (66%), early (19%) and late 
initiators (15%). In all the groups, males comprised a greater proportion thereof, 
constituting 52%, 51% and 51% respectively. 31 
5.3 Timing of antiretroviral therapy initiation 
Age was not a significant factor in respect of whether these PLHIV associated TB 
commenced ART or not. A study in 2006, in relation to those with newly registered 
PLHIV associated TB conducted in Malawi, revealed that age was not a statistically 
significant (p=0.09) predictor of initiating ART. 22 The study recorded two age 
categories, those of less or equal to 35 and above 35 years, a factor which was similar 
to that prevailing in our study (less than 30 and 30 years and above). 22 In our study, 
most participants commencing ART were older than 30 years.  
Slightly more of the early initiators (59%) had a CD4 count less than 200 cells/mm3. 
Nearly three quarters of those without a CD4 count were not on ART, although PLHIV 
associated TB were not supposed to commence ART, dependent on their CD4 count. A 
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study in Iran showed a different scenario where early ART initiation was dependent on 
the CD4 count. 28Those whose CD4 count was less than 100 cells/mm3 were on early 
ART initiation and late initiation was on those whose CD4 count was between 101 and 
200 cells/mm3.  In our study, participants with a CD4 count below 200 cells/mm3 
constituted the largest proportion (56%). Likewise, a study conducted in Durban in 2012 
also had more participants with a CD4 less than 200 cells/mm3. 31 Participants with CD4 
count less than 200 cells/mm3 dominated in all groups of immediate initiators, early 
initiators and delayed initiators when compared to those with CD4 count above 200 
cells/mm3.31 
5.4 TB outcomes depending on stage of antiretroviral therapy initiation 
This study provides the important observation, that in Lesotho, the implementation of 
ART initiation policy in adults living with HIV associated TB is sub-optimal. About three 
quarters of those living with HIV and AIDS were on ART whilst only one third were 
initiated on ART early. This occurred in spite of HIV and TB services being provided 
under one roof. Health care workers responsible for TB and HIV services reported that 
some of the reasons for a delay in starting ART involved the shortage of ARVs and a of 
training among some nurses who were designated to provide integrated HIV and TB 
care. The Lesotho National Antiretroviral Therapy Guidelines recommends that those 
living with HIV associated TB be initiated on ART immediately (within two to four weeks) 
after commencing TB treatment. 2 This latter finding in our study is of a similar nature to 
which was reported in Durban in 2013, where late initiators were 6/100 per-year 
compared with early initiators were 5.7/100 per-year.16 On the other hand, the Lesotho 
finding was contrary to what was observed in a study conducted in Thailand in 2012, 
where more than half (79 out of 156; 51%) of the patients living with HIV associated TB 
were started on ART early. 26  
This study, however demonstrated that the phenomenon of favourable treatment 
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outcomes was not dependent on initiating ART early. There was no difference in TB 
outcomes between early (Prevalence Ratio 1.97) and late ART initiation (Prevalence 
Ratio 1.87). However, there were discrepancies in the Odds Ratio and prevalence ratio 
for the same exposure and outcomes. The Odds Ratio overestimates the association 
between timing of ART initiation and a successful outcome. The OR was 6.2 in early 
initiators and 5.6 in late initiators relative to those who did not commence ART. The 
prevalence ratio was 1.91 and 1.87 for the same exposures and outcomes. The Odds 
Ratio is overestimated when the occurrence of the outcome variable is greater than 0.1 
which was the case in our study. It is, however, much easier to calculate the adjusted 
Odds Ratio using logistic regression, and this finding is commonly reported in cross-
sectional studies where prevalence is the measure of disease occurrence measured. 
Moreover, when assessing association between the stage when ART commenced and 
successful TB treatment, results showed that there existed a significant statistical 
difference in those started early on ART and those who started late (OR 2.4: 95% CI: 
1.3 to 4.7). In a study conducted in Durban in 2012, the opposite phenomenon was 
observed, where timing of initiation of ART was not statistically associated with either 
increased survival or decreased mortality. 31    
Previous studies have demonstrated that early initiation of ART in people living with HIV 
associated TB increased survival and improvement of CD4 cell count, weight and 
suppression of viral load. Nevertheless, the variable which was measured in this study 
was CD4 count and the opposite was observed in Lesotho, where there was no 
association (p=0.07). A study conducted in Durban in 2013 confirmed that initiating ART 
early in people living with HIV associated TB improves survival even in patients with low 
CD4 counts. 16 This particular report, based on the SAPiT trial compared early ART 
initiation (within 4 weeks of commencing TB therapy) and late initiation of ART (between 
4 and 12 weeks of commencing TB treatment) among 642 South Africans infected with 
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HIV and smear-positive pulmonary TB confirmed the efficacy of early initiation. 16  There 
was however, with a marginal significance in the incidence of AIDS or occurrence of 
death among patients with CD4 count less than 50 cell/µ of 8.5 and 26.3 cases per 
person-years (incidence-rate ratio 0.32; 95% CI: 0.07 to 1.13; p=0.06) in the early and 
late ART initiation groups respectively.16  
Moreover, results revealed that there were more males (54%) than females (46%) who 
participated in the study. However, there was no association between sex and 
successful TB treatment (p=0.37). Regarding age, the group of 30 and above was more 
frequent (173/247, 70%). The finding in our study is similar to that obtained in a study 
conducted in Durban in 2012 where the common age was 35 in those initiated on ART 
immediately, early and late. There was however no statistical significance (p=0.59). 31 
Concerning association of age and successful TB outcomes, results showed that there 
was no statistical significance (p=0.50). 
Participants who were confirmed with TB for the first time and were classified as 
category 1 constituted above 90% of all participants. There was, however no statistical 
difference between type of patient and successful TB outcome (p=0.35). The results 
further revealed that Pulmonary TB, was more common (226/247, 91%) than extra-
pulmonary TB the latter which constituted only 21(9%) participants. Although 
participants with Pulmonary TB and those with extra-pulmonary TB retained equal 
chances of having successful TB outcomes, there was no statistical significance 
(p=0.26).  
5.5 Factors associated with treatment outcomes 
Logistic regression was used to assess factors associated with TB treatment outcomes 
and the output resulted in unadjusted and adjusted results.  
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5.5.1 Unadjusted findings 
A bivariate analysis was conducted to assess individual association of the explanatory 
variables namely age, hospital, gender, site of TB, type of TB, CD4 count and stage 
where ART was initiated with the response variable successful treatment where the two 
outcomes; completed and cured were aggregated. The output revealed that hospital 
was marginally significant (p=0.063) and CD4 count and stage ART were highly 
significant as shown by p-value p=0.011 and p<0.001 respectively. The rest of the 
variables were not statistically significant. This is similar to what was illustrated by a 
study in Durban, where CD4 count and ART initiation were statistically significant; 
p<0.001 and p<0.001 respectively; when associated with timing of ART initiation.31 
5.5.2 Adjusted findings 
On multivariate analysis, which was mainly for controlling of confounders, only hospital 
(p=0.04) and stage ART initiated (p<0.001) were independently associated with 
successful TB treatment outcomes. In this analysis, age and gender were included by 
virtue of being confounders even though they were not significant in the univariate 
analysis. This finding continues to confirm that it remains important to initiate PLHIV 
associated TB on ART. A similar finding was observed in a study conducted in India in 
2010 where researchers reported a 50% lower mortality among patients who started 
ART during tuberculosis treatment, compared with those among patients who waited 
until TB therapy had been completed. 10 There were also limitations in this study that 
have been elaborated below. 
5.6 Limitations 
The study had a number of limitations which included selection bias, information bias, 
confounding and precision problems. 
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5.6.1 Selection bias 
There was some selection bias inherent in the study. The study sample comprised only 
three out of 17 hospitals in Lesotho and all the selected hospitals are situated in the 
lowland areas of Lesotho. Access to health care services for people in the highlands is 
more of a challenge and highland hospitals could have had worse TB outcomes.  
The required sample size from one of the hospitals (Scott) was not achieved because of 
duplication of patients’ data in the TB register. The total sample size was maintained by 
increasing the sample size from another hospital thus, but this could have reduced the 
representivity of the results in favour of the hospital that was over-represented. 
The response rate was high as this was a record review, so there was no participation 
refusal. In this study we included participants from the age of 15 years as this is the age 
an adult is defined in Lesotho and not 18 years as in most other countries in Africa. 
Consequently, for comparison purposes, this was a limitation. However, only 2 of the 
247 (0.8%) participants were aged between 15 and 18 years so this contributed little to 
selection bias.  
5.6.2 Information bias 
Measures were observed in this study to minimize information bias. All the participants 
were one the same TB and HIV therapy according to the national guidelines.  
This was a record review and, as a result, results were dependent on the quality of the 
data recorded by clinicians and data collectors who are not researchers and may not 
have had rigor of categorization, collection and recording that one would have 
preferably desired.  
In the period under review, Lesotho encountered a national problem of running out for 
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re-agents used for obtaining CD4 count for people living with HIV. This inadequacy, as 
a result, affected even the study participants. The health care workers reported that the 
problem occurred due to constraints with the national budget. Some participants, 
therefore, reported CD4 count results, which were not obtained from hospitals where 
they were initiated on ART. This factor also was a limitation, in that, different machines 
were used and so there was no standardization when measuring CD4 count. 
There was also a plan to carry out a pilot study before the main data collection but this 
was not possible for the researcher to do due to time constraint. This, however, affected 
the result adversely because the researcher only learned during data analysis that 
range of age categories was wrong. Thus, if a proper pilot study had been conducted 
and its data had been processed, the researcher could have picked up that something 
was wrong with age categories. It was however, a lesson for a researcher and such a 
mistake will not be repeated. In addition, weight results were also not found in the 
registers and it was clarified that they were recorded in the TB patient cards, which they 
take home with them. Had there been a pilot study, the researcher could have noticed 
this defect and such a problem could have been rectified.  
 
5.6.3 Precision problems 
The required sample size for the study was ascertained by a biostatistician prior to 
commencing the study. Because of resources constraints this was limited. Due to a sub-
optimal sample size, the confidence intervals were wide thereby affecting the precision 
of the study. Thus, the dependency on this study is likely to be questioned due to this 




5.6.4 Confounding problems 
The study had confounders, such as viral load and weight, which were not measured 
because they were not available in the TB register. However, health care workers 
reported that viral load tests are not undertaken for everyone in Lesotho unless there is 
an imperative need because they are expensive; the consequence was that all 
participants did not have viral load results. This adversely affected the results in that the 





6 CHAPTER SIX: CONCLUSION AND RECOMMENDATIONS 
This chapter presents conclusions based on the findings and discussions made on each 
issue explored in the study. 
6.1 Conclusion 
This study contributed to the assessment as to whether health services in Lesotho are 
initiating people living with HIV associated TB on ART at the appropriate times after 
commencing TB treatment and whether the TB treatment outcomes are affected by 
ART timing. The study found that whether patients were initiated on ART early or late, 
they were more likely to have a successful TB treatment outcome than if not initiated on 
ART. There was not difference whether initiated early or late. This is contrary to other 
studies, which suggested early initiation of ART after TB treatment was associated with 
better survival and favourable outcomes.9 There was no statistical difference in timing of 
ART initiation and successful TB treatment outcomes even after adjustment for potential 
confounders including age, CD4 count and gender. 
Not all confounders were measured. This included obtaining the patients viral load and 
weight, which were not routinely recorded in the TB register and thus could not be 
collected. As a result a measure of clinical improvement could not be ascertained. The 
improvement in the health status of participants was not an outcome measure used in 
this study.  
 
The study sample was obtained from three hospitals in Lesotho. This however was a 
limitation in itself because if more hospitals were sampled, they could have been more 
representivity of all hospitals in Lesotho.  Participants included both sexes from the age 
of 15, they had different types of TB; either new categories or other categories. The site 
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of TB was different also, it was either PTB or EPTB and they had different CD4 count 
results. Of all the above mentioned factors, only those concerning hospital, CD4 count 
and stage ART initiated were statistically significant in univariate analysis  were 
associated with successful TB treatment outcomes. In multivariate analysis, only 
hospital and stage ART initiated remained statistically significant. 
 
6.2 Recommendations  
6.2.1 The Lesotho Ministry of Health should enforce early initiation of ART in people 
with HIV associated TB in order to have even better results. This can be 
done by hiring monitoring and evaluation officers for all hospitals and they 
will be responsible for regular reporting so that when there are problems, 
they can be addressed at early stage. This can also be achieved by the high 
level involvement of organizations that deal with TB and HIV programs such 
as ICAP Lesotho. 
6.2.2 There should be improvement in record keeping especially in the TB registers 
so that data Lesotho can have access to reliable data. 
6.2.3 For more effectiveness, on-going education through media and community 
campaigns will be imperative as more successful outcomes can be expected. 
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8 CHAPTER EIGHT: APPENDIX 
8.1 Appendix 1: Data collation sheet 
District  Hospital  Date  
Name of person completing the form: 
Checked by:                                  _________________________ 
Patient study number:   __________________________ 
Date TB treatment started: __________________________ 
     
A. Hospital service delivery 
 
1. Is this a government or CHAL hospital?  Gov                  CHAL 
  
 




B. General information about the patient 
 
3. Sex:  Male                Female  
  
 
4. Age:  15-19                 20-29                 30-59                 60+                
  
 
C. TB and HIV patient Information 
 





Treatment after default 
 




6. Treatment Category 
 













8. Clinical Features 
 
a) CD4 Count Specify 




b) Weight in Kilograms Specify 
Weight at the start of TB treatment 
 
 
Date ART initiated 
Tick (√) 
a) < 2 weeks after starting TB treatment  
b) 2-4 weeks after starting TB treatment  
c) > 4 weeks but less than 2 months after starting TB 
treatment 
 
d) 2 months or more after starting TB treatment  
e) Not initiated on ART at all  
62 
 
9. TB Treatment Outcomes 
TB treatment 
outcome if started 








 Cured  
Completed 
 Completed  
Died 
 Died  
Defaulted 
 Defaulted  
Failure 
 Failure  
Transferred out 




8.2 Appendix 2: Request for permission letter from Ntsekhe Hospital 
P.O. Box 13136 
Maseru 100 
Lesotho 
25th May 2012 
 
The Chairperson  
Ntsekhe Hospital Management 
P.O. Box 29 
Mohale’s Hoek 800 
 
Dear Sir/Madam 
RE: PERMISSION TO UNDERTAKE A STUDY AT THE HOSPITAL 
I am a student at the University of KwaZulu-Natal studying Masters of Public Health  
and I hereby request your permission to undertake a study on “Effectiveness of early 
initiation of ART in adults with HIV associated TB in Lesotho in 2012” at your hospital. 
Ntsekhe hospital is among the three hospitals in Lesotho that have been selected to 
represent the country.  
The purpose of the study is to complete the above mentioned degree as it contributes 
50% of the evaluation. The areas of focus will be TB clinic and ART corner where the 
patients’ files will be reviewed as a way of data collection. The TB registers will however 
be used as the primary source of data as I will be looking at HIV positive adults started 
on TB treatment.  Data collection will commence in April 2013 as the study will be 
looking at the cohort of January to March 2012 whose treatment outcomes will be 
obtainable by April 2013. Final results will definitely be shared with the hospital.  
I hope my plea will be approved in your favourable office and I humbly ask that you 
write a letter of acceptance that I can produce at the beginning of the study during data 
collection. 
Yours sincerely, 
Maletsatsi Lenela (mlenela@gmail.com, Cell: +26658003751)   
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8.3 Appendix 3: Request for permission letter from Berea Hospital 
P.O. Box 13136 
Maseru 100 
Lesotho 
25th May 2012 
 
The Chairperson  
Berea Hospital Management 




RE: PERMISSION TO UNDERTAKE A STUDY AT THE HOSPITAL 
I am a student at the University of KwaZulu-Natal studying Masters of Public Health  
and I hereby request your permission to undertake a study on “Effectiveness of early 
initiation of ART in adults with HIV associated TB in Lesotho in 2012” at your hospital. 
Berea hospital is among the three hospitals in Lesotho that have been selected to 
represent the country.  
The purpose of the study is to complete the above mentioned degree as it contributes 
50% of the evaluation. The areas of focus will be TB clinic and ART corner where the 
patients’ files will be reviewed as a way of data collection. The TB registers will however 
be used as the primary source of data as I will be looking at HIV positive adults started 
on TB treatment.  Data collection will commence in April 2013 as the study will be 
looking at the cohort of January to March 2012 whose treatment outcomes will be 
obtainable by April 2013. Final results will definitely be shared with the hospital.  
I hope my plea will be approved in your favourable office and I humbly ask that you 
write a letter of acceptance that I can produce at the beginning of the study during data 
collection. 
Yours sincerely, 
Maletsatsi Lenela (mlenela@gmail.com, Cell: +26658003751)  
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8.4 Appendix 4: Request for permission letter from Scott Hospital 
P.O. Box 13136 
Maseru 100 
Lesotho 
25th May 2012 
 
The Chairperson  
Scott Hospital Management 
Private Bag 190 
Morija, Lesotho  
Dear Sir/Madam 
RE: PERMISSION TO UNDERTAKE A STUDY AT THE HOSPITAL 
I am a student at the University of KwaZulu-Natal studying Masters of Public Health  
and I hereby request your permission to undertake a study on “Effectiveness of early 
initiation of ART in adults with HIV associated TB in Lesotho in 2012” at your hospital. 
Scott hospital is among the three hospitals in Lesotho that have been selected to 
represent the country. The purpose of the study is to complete the above mentioned 
degree as it contributes 50% of the evaluation. The areas of focus will be TB clinic and 
ART corner where the patients’ files will be reviewed as a way of data collection. The 
TB registers will however be used as the primary source of data as I will be looking at 
HIV positive adults started on TB treatment.  Data collection will commence in April 
2013 as the study will be looking at the cohort of January to March 2012 whose 
treatment outcomes will be obtainable by April 2013. Final results will definitely be 
shared with the hospital. I hope my plea will be approved in your favourable office and I 
humbly ask that you write a letter of acceptance that I can produce at the beginning of 
the study during data collection. 
Yours sincerely, 
Maletsatsi Lenela (mlenela@gmail.com, Cell: +26658003751)  
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8.6 Appendix 6: Registration of the project with the school of nursing and public 
health research and higher degrees committee 
 
  
  


